Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H101 Combined with Lenvatinib and Toripalimab in Advanced Biliary Tract Cancer
NCT06919848Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Oncorine in biliary tract cancer (BTC) (2 arms), sponsored by Fudan University. Primary endpoint: Overall Survival at 42 months. Planned start May 2025; status: not yet recruiting.
02
Drugs
Oncorine
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06919848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06919848.